UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?

Peters, L; Cozzi-Lepri, A; Hepatitis C Working Group for the Collaboration of Observational, .; (2016) Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? AIDS , 31 (5) pp. 661-668. 10.1097/QAD.0000000000001378. Green open access

[img]
Preview
Text
Cozzi-Lepri_00002030-900000000-97592.pdf

Download (808kB) | Preview

Abstract

BACKGROUND: Long-term clinical outcomes after HCV treatment of HIV/HCV patients are not well described. We aimed to compare the risk of all-cause and liver-related death according to HCV treatment response in HIV/HCV patients in the multi-cohort study COHERE. METHODS: All patients who had started PEG-interferon + ribavirin (baseline) and followed for ≥72 weeks after baseline were included. Patients were categorized into three response groups depending on treatment duration and HCV-RNA measured in the window 24-72 weeks after baseline. Patients who received ≥24 weeks of therapy were defined as responders if their last HCV-RNA measured between 24-72 weeks after baseline was negative, and having "unknown response" if HCV-RNA was unknown. Non-responders were treated for less than 24 weeks or were HCV-RNA+ between 24-72 weeks after baseline.Mortality rates were compared using survival analysis, and Cox regression used to compare hazard ratios of death between response groups. RESULTS: 3,755 patients were included: 1031 (27.5%) responders, 1,639 (43.6%) non-responders and 1085 (28.9%) with unknown response. Rates (per 1,000 PYFU, 95% CI) of all-cause death were 17.59 (14.88-20.78), 10.43 (7.62-14.28) and 11.00 (8.54-14.23) for non-responders, responders and unknown responders, respectively. After adjustment, the relative hazard (non-responders vs. responders) for all-cause death, liver-related death and non-liver-related death was 1.53 (95% CI 1.06-2.22), 3.39 (95% CI 1.32-8.75) and 1.22 (95% CI 0.80-1.84), respectively. CONCLUSION: HIV/HCV patients with a favourable virological response to PEG-interferon + ribavirin had reduced risk of all-cause and liver-related death, while there was no difference in risk of non-liver-related death when comparing responders and non-responders.

Type: Article
Title: Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/QAD.0000000000001378
Publisher version: http://dx.doi.org/10.1097/QAD.0000000000001378
Language: English
Additional information: Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. This is a non-final version of an article published in final form in Peters, L; Cozzi-Lepri, A; Hepatitis C Working Group for the Collaboration of Observational; (2016) Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? AIDS 10.1097/QAD.0000000000001378
Keywords: HIV; HEPATITIS C; HCV; MORTALITY; INTERFERON; RIBAVIRIN
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/1534365
Downloads since deposit
10Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item